Nucleoside and nucleotide analogs select in culture for different patterns of drug resistance in human immunodeficiency virus types 1 and 2

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 2, 2009, Pages 708-715

  Ntemgwa, Michel L ^a,b   Toni, Thomas D'Aquin ^a   Brenner, Bluma G ^a   Oliveira, Maureen ^a   Asahchop, Eugene L ^a   Moisi, Daniela ^a   Wainberg, Mark A ^a,b,c  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; DIDANOSINE; EMTRICITABINE; LAMIVUDINE; NUCLEOSIDE ANALOG; NUCLEOTIDE DERIVATIVE; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; GENE MUTATION; GENETIC POLYMORPHISM; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; MONONUCLEAR CELL; NUCLEOTIDE SEQUENCE; PHYLOGENY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; VIRUS CULTURE; VIRUS GENE; VIRUS REPLICATION;

ALLELES; AMINO ACID SEQUENCE; ANTI-HIV AGENTS; CELLS, CULTURED; DNA, VIRAL; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV-1; HIV-2; HUMANS; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; NUCLEOSIDES; NUCLEOTIDES; PLASMIDS; POLYMORPHISM, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL;

EID: 59749087787     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01109-08     Document Type: Article

References (53)

1. Adje-Toure, C. A., R. Cheingsong, J. G. Garcia-Lerma, S. Eholie, M. Y. Borget, J. M. Bouchez, R. A. Otten, C. Maurice, M. Sassan-Morokro, R. E. Ekpini, M. Nolan, T. Chorba, W. Heneine, and J. N. Nkengasong. 2003. Antiretroviral therapy in HIV-2-infected patients: changes in plasma viral load, CD4+ cell counts, and drug resistance profiles of patients treated in Abidjan, Cote d'Ivoire. AIDS 17(Suppl. 3):S49-S54.
2. Beatty, C., M. Bradley, D. Brambilla, F. Breakenridge, J. W. Bremer, J. Dragavon, B. Ladd, D. Livnat, C. Michels, C. Mundy, V. Price, T. Ramacciotti, P. Reichelderfer, B. Staes, C. Starkey, and M. Winters. 1997, posting date. DAIDS virology manual for HIV laboratories. Publication NIH-97-3939. U.S. Department of Health and Human Services, Washington, DC. http://www.niaid.nih. gov/daids/vir-manual/full-vir-manual.pdf.
3. Boyer, P. L., S. G. Sarafianos, P. K. Clark, E. Arnold, and S. H. Hughes. 2006. Why do HIV-1 and HIV-2 use different pathways to develop AZT resistance? PLoS Pathog. 2:e10.
4. Brandin, E., L. Lindborg, K. Gyllensten, C. Brostrom, L. Hagberg, M. Gisslen, B. Tuvesson, A. Blaxhult, and J. Albert. 2003. pol gene sequence variation in Swedish HIV-2 patients failing antiretroviral therapy. AIDS Res. Hum. Retrovir. 19:543-550.
5. Brenner, B. G., M. Oliveira, F. Doualla-Bell, D. D. Moisi, M. Ntemgwa, F. Frankel, M. Essex, and M. A. Wainberg. 2006. HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture. AIDS 20:F9-F13.
6. Brenner, B. G., J. P. Routy, M. Petrella, D. Moisi, M. Oliveira, M. Detorio, B. Spira, V. Essabag, B. Conway, R. Lalonde, R. P. Sekaly, and M. A. Wainberg. 2002. Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection. J. Virol. 76:1753-1761.
7. Calvez, V., D. Costagliola, D. Descamps, A. Yvon, G. Collin, A. Cecile, C. Delaugerre, F. Damond, A. G. Marcelin, S. Matheron, A. Simon, M. A. Valantin, C. Katlama, and F. Brun-Vezinet. 2002. Impact of stavudine phenotype and thymidine analogues mutations on viral response to stavudine plus lamivudine in ALTIS 2 ANRS trial. Antivir. Ther. 7:211-218.
8. Colson, P., M. Henry, N. Tivoli, H. Gallais, J. A. Gastaut, J. Moreau, and C. Tamalet. 2005. Polymorphism and drug-selected mutations in the reverse transcriptase gene of HIV-2 from patients living in southeastern France. J. Med. Virol. 75:381-390.
9. Damond, F., S. Matheron, G. Peytavin, P. Campa, A. Taieb, G. Collin, C. Delaunay, G. Chene, F. Brun-Vezinet, and D. Descamps. 2004. Selection of K65R mutation in HIV-2-infected patients receiving tenofovir-containing regimen. Antivir. Ther. 9:635-636.
10. De Cock, K. M., G. Adjorlolo, E. Ekpini, T. Sibailly, J. Kouadio, M. Maran, K. Brattegaard, K. M. Vetter, R. Doorly, and H. D. Gayle. 1993. Epidemiology and transmission of HIV-2. Why there is no HIV-2 pandemic. JAMA 270:2083-2086.
11. Descamps, D., F. Damond, S. Matheron, G. Collin, P. Campa, S. Delarue, S. Pueyo, G. Chene, and F. Brun-Vezinet. 2004. High frequency of selection of K65R and Q151M mutations in HIV-2 infected patients receiving nucleoside reverse transcriptase inhibitors containing regimen. J. Med. Virol. 74:197-201.
12. Doualla-Bell, F., A. Avalos, B. Brenner, T. Gaolathe, M. Mine, S. Gaseitsiwe, M. Oliveira, D. Moisi, N. Ndwapi, H. Moffat, M. Essex, and M. A. Wainberg. 2006. High prevalence of the K65R mutation in human immunodeficiency virus type 1 subtype C isolates from infected patients in Botswana treated with didanosine-based regimens. Antimicrob. Agents Chemother. 50:4182-4185.
13. Gao, F., L. Yue, D. L. Robertson, S. C. Hill, H. Hui, R. J. Biggar, A. E. Neequaye, T. M. Whelan, D. D. Ho, G. M. Shaw, et al. 1994. Genetic diversity of human immunodeficiency virus type 2: evidence for distinct sequence subtypes with differences in virus biology. J. Virol. 68:7433-7447.
14. Gao, F., L. Yue, P. M. Sharp, and B. H. Hahn. 1993. Genetic typing of HIV-2 from a Senegalese/German heterosexual transmission. AIDS Res. Hum. Retrovir. 9:703-704.
15. Gao, Q., Z. Gu, J. Hiscott, G. Dionne, and M. A. Wainberg. 1993. Generation of drug-resistant variants of human immunodeficiency virus type 1 by in vitro passage in increasing concentrations of 2′,3′- dideoxycytidine and 2′,3′-dideoxy-3′-thiacytidine. Antimicrob. Agents Chemother. 37:130-133.
16. Gao, Q., Z. Gu, M. A. Parniak, J. Cameron, N. Cammack, C. Boucher, and M. A. Wainberg. 1993. The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2′,3′-dideoxy-3′-thiacytidine. Antimicrob. Agents Chemother. 37:1390-1392.
17. Gao, Q., Z. X. Gu, M. A. Parniak, X. G. Li, and M. A. Wainberg. 1992. In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3′-azido-3′-deoxythymidine and 2′,3′- dideoxyinosine. J. Virol. 66:12-19.
18. Grant, R. M., D. R. Kuritzkes, V. A. Johnson, J. W. Mellors, J. L. Sullivan, R. Swanstrom, R. T. D'Aquila, M. Van Gorder, M. Holodniy, R. M. Lloyd, Jr., C. Reid, G. F. Morgan, and D. L. Winslow. 2003. Accuracy of the TRUGENE HIV-1 genotyping kit. J. Clin. Microbiol. 41:1586-1593.
19. Guyader, M., M. Emerman, P. Sonigo, F. Clavel, L. Montagnier, and M. Alizon. 1987. Genome organization and transactivation of the human immunodeficiency virus type 2. Nature 326:662-669.
20. Hall, T. A. 1999. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucleic Acids Symp. Ser. 41:95-98.
21. Hu, Z., F. Giguel, H. Hatano, P. Reid, J. Lu, and D. R. Kuritzkes. 2006. Fitness comparison of thymidine analog resistance pathways in human immunodeficiency virus type 1. J. Virol. 80:7020-7027.
22. Jallow, S., S. Kaye, A. Alabi, A. Aveika, R. Sarge-Njie, S. Sabally, T. Corrah, H. Whittle, G. Vanham, S. Rowland-Jones, W. Janssens, and S. J. McConkey. 2006. Virological and immunological response to Combivir and emergence of drug resistance mutations in a cohort of HIV-2 patients in The Gambia. AIDS 20:1455-1458.
23. Johnson, V. A., F. Brun-Vezinet, B. Clotet, H. F. Gunthard, D. R. Kuritzkes, D. Pillay, J. M. Schapiro, and D. D. Richman. 2007. Update of the drug resistance mutations in HIV-1: 2007. Top. HIV Med. 15:119-125.
24. Johnson, V. A., F. Brun-Vezinet, B. Clotet, D. R. Kuritzkes, D. Pillay, J. M. Schapiro, and D. D. Richman. 2006. Update of the drug resistance mutations in HIV-1: fall 2006. Top. HIV Med. 14:125-130.
25. Kanki, P. J., M. Peeters, and A. Gueye-Ndiaye. 1997. Virology of HIV-1 and HIV-2: implications for Africa. AIDS 11(Suppl. B):S33-S42.
26. Keulen, W., N. K. Back, A. van Wijk, C. A. Boucher, and B. Berkhout. 1997. Initial appearance of the 184Ile variant in lamivudine-treated patients is caused by the mutational bias of human immunodeficiency virus type 1 reverse transcriptase. J. Virol. 71:3346-3350.
27. Kumar, S., K. Tamura, and M. Nei. 2004. MEGA3: integrated software for molecular evolutionary genetics analysis and sequence alignment. Brief. Bioinform. 5:150-163.
28. Kuritzkes, D. R., R. M. Grant, P. Feorino, M. Griswold, M. Hoover, R. Young, S. Day, R. M. Lloyd, Jr., C. Reid, G. F. Morgan, and D. L. Winslow. 2003. Performance characteristics of the TRUGENE HIV-1 genotyping kit and the Opengene DNA sequencing system. J. Clin. Microbiol. 41:1594-1599.
29. Larder, B. A., G. Darby, and D. D. Richman. 1989. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243:1731-1734.
30. Loemba, H., B. Brenner, M. A. Parniak, S. Ma'ayan, B. Spira, D. Moisi, M. Oliveira, M. Detorio, M. Essex, and M. A. Wainberg. 2002. Polymorphisms of cytotoxic T-lymphocyte (CTL) and T-helper epitopes within reverse transcriptase (RT) of HIV-1 subtype C from Ethiopia and Botswana following selection of antiretroviral drug resistance. Antivir. Res. 56:129-142.
31. Loemba, H., B. Brenner, M. A. Parniak, S. Ma'ayan, B. Spira, D. Moisi, M. Oliveira, M. Detorio, and M. A. Wainberg. 2002. Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against nonnucleoside inhibitors of RT. Antimicrob. Agents Chemother. 46:2087-2094.
32. Margot, N. A., J. M. Waters, and M. D. Miller. 2006. In vitro human immunodeficiency virus type 1 resistance selections with combinations of tenofovir and emtricitabine or abacavir and lamivudine. Antimicrob. Agents Chemother. 50:4087-4095.
33. Marlink, R., P. Kanki, I. Thior, K. Travers, G. Eisen, T. Siby, I. Traore, C. C. Hsieh, M. C. Dia, E. H. Gueye, et al. 1994. Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science 265:1587-1590.
34. Ntemgwa, M., B. G. Brenner, M. Oliveira, D. Moisi, and M. A. Wainberg. 2007. Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors. Antimicrob. Agents Chemother. 51:604-610.
35. Owen, S. M., D. Ellenberger, M. Rayfield, S. Wiktor, P. Michel, M. H. Grieco, F. Gao, B. H. Hahn, and R. B. Lal. 1998. Genetically divergent strains of human immunodeficiency virus type 2 use multiple coreceptors for viral entry. J. Virol. 72:5425-5432.
36. Palmer, S., M. Kearney, F. Maldarelli, E. K. Halvas, C. J. Bixby, H. Bazmi, D. Rock, J. Falloon, R. T. Davey, Jr., R. L. Dewar, J. A. Metcalf, S. Hammer, J. W. Mellors, and J. M. Coffin. 2005. Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. J. Clin. Microbiol. 43: 406-413.
37. Parikh, U. M., L. Bacheler, D. Koontz, and J. W. Mellors. 2006. The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations. J. Virol. 80:4971-4977.
38. Parikh, U. M., D. C. Barnas, H. Faruki, and J. W. Mellors. 2006. Antagonism between the HIV-1 reverse-transcriptase mutation K65R and thymidine-analogue mutations at the genomic level. J. Infect. Dis. 194:651-660.
39. Parikh, U. M., S. Zelina, N. Sluis-Cremer, and J. W. Mellors. 2007. Molecular mechanisms of bidirectional antagonism between K65R and thymidine analog mutations in HIV-1 reverse transcriptase. AIDS 21:1405-1414.
40. Petrella, M., M. Oliveira, D. Moisi, M. Detorio, B. G. Brenner, and M. A. Wainberg. 2004. Differential maintenance of the M184V substitution in the reverse transcriptase of human immunodeficiency virus type 1 by various nucleoside antiretroviral agents in tissue culture. Antimicrob. Agents Chemother. 48:4189-4194.
41. Reid, P., H. MacInnes, M. E. Cong, W. Heneine, and J. G. Garcia-Lerma. 2005. Natural resistance of human immunodeficiency virus type 2 to zidovudine. Virology 336:251-264.
42. Ren, J., L. E. Bird, P. P. Chamberlain, G. B. Stewart-Jones, D. I. Stuart, and D. K. Stammers. 2002. Structure of HIV-2 reverse transcriptase at 2.35-A resolution and the mechanism of resistance to non-nucleoside inhibitors. Proc. Natl. Acad. Sci. USA 99:14410-14415.
43. Rodes, B., A. Holguin, V. Soriano, M. Dourana, K. Mansinho, F. Antunes, and J. Gonzalez-Lahoz. 2000. Emergence of drug resistance mutations in human immunodeficiency virus type 2-infected subjects undergoing antiretroviral therapy. J. Clin. Microbiol. 38:1370-1374.
44. Salomon, H., A. Belmonte, K. Nguyen, Z. Gu, M. Gelfand, and M. A. Wainberg. 1994. Comparison of cord blood and peripheral blood mononuclear cells as targets for viral isolation and drug sensitivity studies involving human immunodeficiency virus type 1. J. Clin. Microbiol. 32:2000-2002.
45. Saracino, A., L. Monno, L. Scudeller, D. C. Cibelli, A. Tartaglia, G. Punzi, C. Torti, S. Lo Caputo, F. Mazzotta, G. Scotto, G. Carosi, and G. Angarano. 2006. Impact of unreported HIV-1 reverse transcriptase mutations on phenotypic resistance to nucleoside and non-nucleoside inhibitors. J. Med. Virol. 78:9-17.
46. Schulz, T. F., D. Whitby, J. G. Hoad, T. Corrah, H. Whittle, and R. A. Weiss. 1990. Biological and molecular variability of human immunodeficiency virus type 2 isolates from The Gambia. J. Virol. 64:5177-5182.
47. Simon, F., S. Matheron, C. Tamalet, I. Loussert-Ajaka, S. Bartczak, J. M. Pepin, C. Dhiver, E. Gamba, C. Elbim, J. A. Gastaut, et al. 1993. Cellular and plasma viral load in patients infected with HIV-2. AIDS 7:1411-1417.
48. Smith, R. A., G. S. Gottlieb, D. J. Anderson, C. L. Pyrak, and B. D. Preston. 2008. Human immunodeficiency virus types 1 and 2 exhibit comparable sensitivities to zidovudine and other nucleoside analog inhibitors in vitro. Antimicrob. Agents Chemother. 52:329-332.
49. Sosa, N., C. Hill-Zabala, E. Dejesus, G. Herrera, A. Florance, M. Watson, C. Vavro, and M. Shaefer. 2005. Abacavir and lamivudine fixed-dose combination tablet once daily compared with abacavir and lamivudine twice daily in HIV-infected patients over 48 weeks (ESS30008, SEAL). J. Acquir. Immune Defic. Syndr. 40:422-427.
50. Tisdale, M., T. Alnadaf, and D. Cousens. 1997. Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89. Antimicrob. Agents Chemother. 41:1094-1098.
51. Tuaillon, E., M. Gueudin, V. Lemee, I. Gueit, P. Roques, G. E. Corrigan, J. C. Plantier, F. Simon, and J. Braun. 2004. Phenotypic susceptibility to nonnucleoside inhibitors of virion-associated reverse transcriptase from different HIV types and groups. J. Acquir. Immune Defic. Syndr. 37:1543-1549.
52. Wainberg, M. A. 2004. The impact of the M184V substitution on drug resistance and viral fitness. Expert Rev. Anti-Infect. Ther. 2:147-151.
53. Witvrouw, M., C. Pannecouque, W. M. Switzer, T. M. Folks, E. De Clercq, and W. Heneine. 2004. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antivir. Ther. 9:57-65.